Related Experiment Video
Updated: Dec 18, 2025

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Mechanical Mitral Valve Replacement: A Multicenter Study of Outcomes With Use of 15- to 17-mm Prostheses
Rinske J IJsselhof1, Martijn G Slieker2, Kimberlee Gauvreau3
1Department of Pediatric Cardiac Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.
Background:
The aim of this study was to evaluate early and mid-term outcomes (mortality and prosthetic valve reintervention) after mitral valve replacement with 15- to 17-mm mechanical prostheses.
Methods:
A multicenter, retrospective cohort study was performed among patients who underwent mitral valve replacement with a 15- to 17-mm mechanical prosthesis at 6 congenital cardiac centers: 5 in The Netherlands and 1 in the United States. Baseline, operative, and follow-up data were evaluated.
Results:
Mitral valve replacement was performed in 61 infants (15 mm, n = 17 [28%]; 16 mm, n = 18 [29%]; 17 mm, n = 26 [43%]), of whom 27 (47%) were admitted to the intensive care unit before surgery and 22 (39%) required ventilator support. Median age at surgery was 5.9 months (interquartile range [IQR] 3.2-17.4), and median weight was 5.7 kg (IQR, 4.5-8.8). There were 13 in-hospital deaths (21%) and 8 late deaths (17%, among 48 hospital survivors). Major adverse events occurred in 34 (56%). Median follow-up was 4.0 years (IQR, 0.4-12.5) First prosthetic valve replacement (n = 27 [44%]) occurred at a median of 3.7 years (IQR, 1.9-6.8). Prosthetic valve endocarditis was not reported, and there was no mortality related to prosthesis replacement. Other reinterventions included permanent pacemaker implantation (n = 9 [15%]), subaortic stenosis resection (n = 4 [7%]), aortic valve repair (n = 3 [5%], and aortic valve replacement (n = 6 [10%]).
Conclusions:
Mitral valve replacement with 15- to 17-mm mechanical prostheses is an important alternative to save critically ill neonates and infants in whom the mitral valve cannot be repaired. Prosthesis replacement for outgrowth can be carried out with low risk.
Insights
Mitral valve replacement using small mechanical prostheses in infants is a viable option, demonstrating acceptable early and mid-term outcomes despite high rates of adverse events. Reintervention for outgrowth is low-risk.
Area of Science:
- Cardiovascular Surgery
- Pediatric Cardiology
- Biomedical Engineering
Background:
- Small mechanical prostheses (15-17 mm) are used for mitral valve replacement in infants.
- Outcomes of these small prostheses require evaluation due to potential complications and reinterventions.
Purpose of the Study:
- To assess early and mid-term outcomes, including mortality and reintervention rates, after mitral valve replacement with 15- to 17-mm mechanical prostheses in infants.
Main Methods:
- A multicenter, retrospective cohort study involving 61 infants across 6 congenital cardiac centers.
- Data on baseline, operative, and follow-up parameters were analyzed.
Main Results:
- 13 in-hospital deaths (21%) and 8 late deaths (17%) occurred. Major adverse events were reported in 56% of patients.
- 44% required prosthetic valve reintervention, primarily for outgrowth, with no reported mortality related to these procedures.
Conclusions:
- Mitral valve replacement with 15- to 17-mm mechanical prostheses is a crucial alternative for critically ill infants unsuitable for mitral valve repair.
- Prosthesis replacement due to outgrowth can be performed with minimal risk.
Related Concept Videos
Mitral Stenosis III: Medical Management
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Regurgitation III: Medical Management
Mitral Regurgitation I: Introduction

